Abiopharma

🔍 Collard Craig A (Executive)

Company: HERON THERAPEUTICS, INC. /DE/ (HRTX)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Acquired 34,789 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: M | equity_swap_involved: false | shares_owned_after: 696,841.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 50,021 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: M | equity_swap_involved: false | shares_owned_after: 757,885.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 34,789 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-30 | Code: M | equity_swap_involved: false | shares_owned_after: 382,675.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 50,021 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-30 | Code: M | equity_swap_involved: false | shares_owned_after: 750,316.00 | transaction_form_type: 4 | Footnotes: F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
• F2: Includes 11,023 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026.
• F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
• F4: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.